ClinicalTrials.gg
Not yet recruitingNCT07850752LUMINA IgANUpdated Sep 30, 2026

A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy

A Phase 3 interventional study of zigakibart and atrasentan in IgA Nephropathy (IgAN), sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Planned enrollment
5th of 14
340 · median 108
Started
2026
with 4 others
Phase 3
8 of 18
5 open now
Primary completion
2028-09
later than 5 of 11 live
Registered
18th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 18th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.

Read the detailed description

The study includes a 52-week double-blind treatment period and a 52-week open-label extension (OLE):

  • Double-blind treatment period: Participants will receive zigakibart and either atrasentan or matching placebo. The purpose is to evaluate if zigakibart + atrasentan demonstrates increased efficacy in reducing proteinuria and delaying progression of disease compared to zigakibart + placebo. It also aims to evaluate the safety and tolerability of zigakibart + atrasentan.
  • OLE: Participants will receive zigakibart and atrasentan. The purpose is to provide study participants with the opportunity to continue to receive zigakibart and atrasentan, while enabling continued collection of long-term efficacy, safety, and tolerability data.
03

Conditions studied

  • IgA Nephropathy (IgAN)

Keywords

  • Zigakibart
  • Atrasentan
  • IgA nephropathy
  • IgAN
  • Proteinuria
  • UPCR
  • eGFR
  • eGFR slope
  • Kidney function decline
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years at the time of signing the , prior to initiation of any study specific activities/procedures
  • -proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. If a biopsy report within 10 years is not available, re-biopsy may be performed locally during Screening.
  • ≥ 30 mL/min/1.73m2 by a central laboratory at Screening, calculated using serum creatinine based on the 2021 CKD-EPI equation (Inker et al 2021)
  • UPCR ≥ 0.7 g/g (700 mg/g), as measured from a 24 hour urine collection by a central laboratory at Screening
  • Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of SGLT2i, MRA, and/or GLP-1A if stable for at least 12 weeks prior to Screening. Participants are expected to stay on a stable dose of ACEi, ARB, SGLT2i, MRA and/or GLP-1A for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Chronic Kidney Disease (CKD), either clinically suspected or based on , resulting from any condition or another glomerulopathy/podocytopathy other than IgAN
  • Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, disorders or neoplasia
  • Diagnosis of active IgA vasculitis
  • Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (2025)
  • Current clinical diagnosis of nephrotic syndrome
  • Known history of heart failure or conditions relating to fluid overload such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites
  • Current severe infection requiring antimicrobials, or history of recurrent, severe infections as determined by the Investigator

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    zigakibart + atrasentan

    Patients receive zigakibart and atrasentan

    Biological: zigakibart · Drug: atrasentan

  • Active comparator
    zigakibart + placebo

    Patients receive zigakibart and matching placebo

    Biological: zigakibart · Drug: Placebo

Interventions

  • Biologicalzigakibart

    Solution for injection via PFS-NSD

    Also known as: BION-1301, FUB523

  • Tablet

    Also known as: CHK01, EXV811

  • DrugPlacebo

    Tablet

06

What researchers measure

Primary outcomes

  1. Change in proteinuria from Baseline to Week 36, based on 24 hour urine collection

    Relative difference between treatment groups in mean change of natural log 24-hour UPCR from Baseline to Week 36, expressed as percent reduction

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Rate of patients achieving proteinuria remission at Week 52

    Difference between the treatment groups in the rate of patients achieving proteinuria remission, defined as 24-hour UPCR \< 0.5 g/g

    Time frame: Week 52

  2. Rate of proteinuria remission

    Difference between the treatment groups in the rate of proteinuria remission, defined as 24-hour UPCR of \< 0.3 g/g

    Time frame: Week 52

  3. Proportion of participants with AEs, SAEs and AESIs

    Proportion of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of special interest (AESIs)

    Time frame: 128 Weeks

  4. Change from baseline in Glomerular Filtration rate (GFR)

    Change from baseline in GFR (safety laboratory parameters)

    Time frame: Baseline and up to 104 weeks

  5. Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Change from baseline in SBP and DBP (vital signs)

    Time frame: Baseline and up to 104 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Sep 17, 2028
CompletionEst.
Dec 25, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850752
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 17, 2028 (estimated)
Completion
Dec 25, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion